It uniquely addresses both mutational (eg,C797S) and non-mutational resistance mechanisms to third-generation TKIs while sparing wild-type EGFR
CCM-205 treatment results in significant biochemical inhibition of mutant EGFR signaling in tumors, confirming effective target engagement in vivo